Cargando…
Will psilocybin lose its magic in the clinical setting?
Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what psilocybin-assisted psychotherapy might look like in...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036342/ https://www.ncbi.nlm.nih.gov/pubmed/35480296 http://dx.doi.org/10.1177/20451253221090822 |
_version_ | 1784693503731695616 |
---|---|
author | Hayes, Caroline Wahba, Mourad Watson, Stuart |
author_facet | Hayes, Caroline Wahba, Mourad Watson, Stuart |
author_sort | Hayes, Caroline |
collection | PubMed |
description | Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what psilocybin-assisted psychotherapy might look like in the clinical setting. In this narrative review article we have considered the difficulties that may arise as psilocybin emerges from the research setting, which may hamper its progress towards becoming a licenced medication. Psilocybin has its own unique challenges: the expectation patients come to dosing with having read overwhelmingly positive media; patient suggestibility under the influence of psilocybin and requirement for specialised therapists to name a few. We have also made some recommendations for measures that should be taken in both the phase 3 trials and with clinicians to try and minimise some of the issues raised. In doing so our hope is that psilocybin will continue towards becoming a licenced medication that suitable patients are able to access with relative ease. Practicing psychiatrists need to have an awareness of the potential pitfalls of psilocybin as they will be responsible for prescribing it in the future. |
format | Online Article Text |
id | pubmed-9036342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-90363422022-04-26 Will psilocybin lose its magic in the clinical setting? Hayes, Caroline Wahba, Mourad Watson, Stuart Ther Adv Psychopharmacol From Drug Misuse to Useful Drugs Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what psilocybin-assisted psychotherapy might look like in the clinical setting. In this narrative review article we have considered the difficulties that may arise as psilocybin emerges from the research setting, which may hamper its progress towards becoming a licenced medication. Psilocybin has its own unique challenges: the expectation patients come to dosing with having read overwhelmingly positive media; patient suggestibility under the influence of psilocybin and requirement for specialised therapists to name a few. We have also made some recommendations for measures that should be taken in both the phase 3 trials and with clinicians to try and minimise some of the issues raised. In doing so our hope is that psilocybin will continue towards becoming a licenced medication that suitable patients are able to access with relative ease. Practicing psychiatrists need to have an awareness of the potential pitfalls of psilocybin as they will be responsible for prescribing it in the future. SAGE Publications 2022-04-22 /pmc/articles/PMC9036342/ /pubmed/35480296 http://dx.doi.org/10.1177/20451253221090822 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | From Drug Misuse to Useful Drugs Hayes, Caroline Wahba, Mourad Watson, Stuart Will psilocybin lose its magic in the clinical setting? |
title | Will psilocybin lose its magic in the clinical setting? |
title_full | Will psilocybin lose its magic in the clinical setting? |
title_fullStr | Will psilocybin lose its magic in the clinical setting? |
title_full_unstemmed | Will psilocybin lose its magic in the clinical setting? |
title_short | Will psilocybin lose its magic in the clinical setting? |
title_sort | will psilocybin lose its magic in the clinical setting? |
topic | From Drug Misuse to Useful Drugs |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036342/ https://www.ncbi.nlm.nih.gov/pubmed/35480296 http://dx.doi.org/10.1177/20451253221090822 |
work_keys_str_mv | AT hayescaroline willpsilocybinloseitsmagicintheclinicalsetting AT wahbamourad willpsilocybinloseitsmagicintheclinicalsetting AT watsonstuart willpsilocybinloseitsmagicintheclinicalsetting |